Cmax/auc for demonstrating the bioequivalence of two drug products containing levodopa-benserazide
- At: 2005 FIP Congress in Cairo (Egypt)
- Type: Poster
- By: SCHAIQUEVICH, Paula (Lab.Raffo- Univ.Nac. La Plata, Farmacologia, Villa Martelli, Buenos Aires, Argentina)
- Co-author(s): Rubio Garcia (Lab. Raffo, BUENOS AIRES, Argentina)
For evaluating the bioequivalence of two drug products, both the rate and extent of absorption of the two products are expected to be the same within a statistical tolerance. For the rate of absorption, Cmax is often used, an ambiguous measure of the absorption rate for also being affected by the extent of absorption. In the present work we.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.